Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rodolfo Alcedo

Neurological Surgery San Juan, PR Medical Doctor

NPI 1316141534 CMS profile 59764

Camelot Condominium Number 140 Street 842, Apartment 3103, San Juan, PR 00926

Open in the dashboard

General payments

$37,930

136 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rodolfo Alcedo of San Juan, PR is reported in the CMS Open Payments database as having received $37,930 across 136 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,347 25
2024 General $19,970 32
2023 General $4,553 32
2022 General $1,039 11
2021 General $2,336 15
2020 General $449 6
2019 General $1,236 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rodolfo Alcedo
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Rodolfo Alcedo were reported at $8,347. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Rodolfo Alcedo Neurological Surgery median Middle half National median
2019 $1,236 $582 $138–$3,006 $163
2020 $449 $294 $76–$2,174 $114
2021 $2,336 $387 $105–$2,432 $132
2022 $1,039 $542 $139–$2,989 $149
2023 $4,553 $534 $145–$2,697 $160
2024 $19,970 $574 $155–$3,046 $164
2025 $8,347 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Penumbra, Inc. $31,880 67 payments
  2. Medtronic, Inc. $2,978 40 payments
  3. Siemens Medical Solutions USA, Inc. $1,859 10 payments
  4. Imperative Care, INc $175 1 payment
  5. Carl Zeiss Meditec USA, Inc. $157 1 payment
  6. Janssen Pharmaceuticals, Inc $139 3 payments
  7. Olympus Latin America, Inc. $136 2 payments
  8. Medexus Pharma, Inc. $122 1 payment
  9. Globus Medical, Inc. $106 1 payment
  10. MicroVention, Inc. $104 2 payments
  11. Other $274 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $17,768 25 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,000 2 payments
  3. Food and Beverage $8,163 109 payments
Products named General payments · program years 2019–2025
  1. Penumbra System Neurointervention $15,621 18 payments
  2. RED 72 $7,601 15 payments
  3. Smart Coil $7,010 10 payments
  4. Pipeline $1,547 16 payments
  5. Artis icono floor $1,534 6 payments
  6. Artis Q floor $1,481 5 payments
  7. Penumbra SMART Coil $539 5 payments
  8. Penumbra System Neurointervention $524 6 payments
  9. SOLITAIRE X $370 8 payments
  10. VANTAGE ANTERIOR FIXATION SYSTEM $208 3 payments
  11. Other $3,480 60 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

47

Median for Neurosurgery: 83

Drug cost

$372

Median for Neurosurgery: $872

Branded share of claims

100%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 47 $372

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Records

136 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record